نتایج جستجو برای: cholinesterase inhibitors
تعداد نتایج: 191405 فیلتر نتایج به سال:
BACKGROUND Cholinesterases are a group of serine hydrolases that split the neurotransmitter acetylcholine (ACh) and terminate its action. Of the two types, butyrylcholinesterase and acetylcholinesterase (AChE), AChE plays the key role in ending cholinergic neurotransmission. Cholinesterase inhibitors are substances, either natural or man-made that interfere with the break-down of ACh and prolon...
alzheimers disease (ad) is by far the most common cause of dementia. definite diagnosis of ad is based on pathological findings. nincds-adrda criteria, published more than 25 years ago, are commonly used for the clinical diagnosis of ad. however, considering serious shortcomings of these criteria, new criteria have been proposed. according to these new criteria, ad can be diagnosed in predement...
PMH67 CO-PRESCRIBING CHOLINESTERASE INHIBITORS WITH ANTICHOLINERGIC URINARY INCONTINENCE MEDICATIONS
In search of potent inhibitors cholinesterase enzymes and antioxidant agents, synthetic derivatives dihydroquinazolin-4(1H)-one 1-38 were evaluated as potential anti-Alzheimer agents through in vitro acetylcholinesterase (AChE) butyrylcholinesterase (BChE) inhibitions radical (DPPH ABTS) scavenging activities. The (SAR) was mainly based on the different substituents at aryl part which showed a ...
BACKGROUND Cholinesterase inhibitors and memantine are prescribed to slow the progression dementia. Although the efficacy of these drugs has been demonstrated, their effectiveness, from the perspective of patients and caregivers, has been questioned. Little is known about whether the demand for cholinesterase inhibitors and memantine are sensitive to out-of-pocket cost. Using the 2006 implement...
BACKGROUND Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not recommended by th...
BACKGROUND The study aims to quantify the population impact of prescribing cholinesterase inhibitors to slow the cognitive decline in Alzheimer's disease (AD), and to compare with the benefit of treating hypertension to prevent the onset of AD. METHODS Literature review to ascertain the prevalence of AD, benefits of interventions, analysis of local and national surveys to measure the current ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید